Industry-sponsored clinical research

摘要

Over the past decade, India has witnessed a phenomenal growth in the clinical trial industry. The projections forecast a double-digit growth over the next decade propelled by enhanced outsourcing by drag developing companies.Sathyamala has quoted a study undertaken by the Indian Council for Research on International Economic Relations (ICRIER) in the year 2000 to provide inputs to the Commission on Macroeconomics and Health, Government of India. Besides evaluating the existing public health infrastructure and the pharmaceutical industry, the study identified the following as special advantages for health research in India: 'Huge and diverse clinical material [sic] for research giving the country a unique opportunity to turn an acknowledged disadvantage into a research advantage.'A large and diverse population steeped in tradition has ensured that many rarer genetic disorders have survived in India, and this can become the subject matter of valuable research.' India with its strong information technology (IT) base, can take a lead in research areas which require strong software inputs.The study underlined the urgency for capacity building to undertake clinical trials for new molecules likely to be introduced for various communicable diseases.